Vaxxinit
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer`s, Parkinson’s, migraine, and hypercholesterolemia.. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. The key to the platform is the proprietary library of UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Employees:
- 11-100
About Us
We are a global team united in the fight against human suffering.
We are passionate about delivering transformational, science-led innovation that is distinctly accessible for all. Alzheimer’s, Parksinon’s, COVID-19 and other diseases don’t discriminate based on where you live or how much you make, and we believe medicine shouldn’t either.
Our Team
Our team is comprised of leaders in neurobiology, infectious disease, drug development and disruptive ideas.
More Health to More People.
Our vision is to provide cheaper, safer, more convenient, effective medicines for chronic disease to all.
Our mission is to democratize health by pioneering the third biologic revolution.
Our Mission
Our mission is to democratize health through technology by pioneering the third biologic revolution.
For the first time in history, chronic diseases are killing us more than infectious diseases.
One reason is that vaccines, the first biologic revolution, have been so successful and prolific. There are today 29 vaccine-preventable diseases and over 80% of the world is vaccinated. Unfortunately, they have been limited exclusively to infectious diseases.
The innovation of complex biologics, particularly monoclonal antibodies (mAbs), manufactured in bioreactors comprise the second revolution and have been magically effective against certain chronic diseases. Unfortunately, they pose manufacturing challenges, are burdensome to administer, and are extremely expensive, which is why less than 1% of the world currently has the privilege of the medical benefits of mAbs, a small fraction of the global population who actually could benefit.
This leads us to the third biologic revolution.
We are bringing the efficiency of vaccines – which are cheaper, more convenient and accessible – to chronic diseases which leads to a dramatic increase to that 1%. In this instance, we are not stealing market share from the current mAbs, we are expanding the overall addressable market.